Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2025
- Bill Number
- H.R. 3092
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-04-30: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2025-05-21T20:42:23Z
AI-Generated Summary
Purpose
The Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2025 aims to improve the quality, safety, and reliability of electrodiagnostic services (tests that measure electrical activity in nerves and muscles) covered under Medicare, while reducing fraud, waste, and unnecessary procedures. It establishes standards for facilities providing these services to ensure accurate diagnoses and better patient outcomes.
Key Provisions
- Payment Restrictions: Medicare will not pay for specific electrodiagnostic services—nerve conduction studies (which assess nerve signal speed and strength) and needle electromyography tests (which insert a needle electrode into muscles to evaluate electrical activity)—unless they are provided at a "qualified facility." This restriction begins 3 to 4 years after the bill's enactment and does not apply to services used during surgery for real-time nerve monitoring (intraoperative neuromonitoring).
- Qualified Facilities: These are facilities accredited by organizations approved by the Secretary of Health and Human Services (HHS). Accreditation requires facilities to meet standards including:
- A quality assurance program to ensure reliable and safe testing.
- Use of devices that can accurately record and display test results in real-time.
- For needle electromyography, the person performing the test must have at least 3 months of specialized training during an accredited medical residency or fellowship, or equivalent qualifications.
- Results must be interpreted on-site immediately by the person who performed or supervised the test.
- Additional standards set by the HHS Secretary.
- Accreditation Process: Within 2 years of enactment, the HHS Secretary must approve accrediting organizations after consulting an advisory committee. These organizations must enforce the facility standards. The Secretary will issue regulations within 1 year outlining approval, review, and revocation processes for accreditors.
- Advisory Committee: Establishes the National Electrodiagnostic Services Advisory Committee (9–11 non-federal members, including physicians, physical therapists, other practitioners, a patient representative, and others). The committee meets at least twice yearly to advise on standards, regulations, and accreditor approvals, focusing on reducing unnecessary treatments, improving diagnoses, preventing fraud, and enhancing care quality.
Significant Changes to Existing Law
This bill amends Section 1834 of the Social Security Act (which governs Medicare payment rules for certain services) by adding a new subsection (aa). It introduces mandatory accreditation and quality standards for electrodiagnostic services, which were previously unregulated in this way under Medicare. There were no prior federal requirements for facility accreditation, personnel training, or on-site interpretation specifically for these tests, potentially allowing lower-quality or fraudulent services to be reimbursed.
Potential Impacts
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS, part of HHS) will face new administrative responsibilities, including specifying accreditors, issuing regulations, and managing the advisory committee. This could increase oversight costs but help reduce improper Medicare payments through fraud prevention.
- On Citizens: Medicare beneficiaries (primarily older adults or those with disabilities needing nerve/muscle testing) may benefit from more reliable diagnoses, fewer repeat tests, and reduced risks from unqualified providers, leading to better health outcomes and lower unnecessary healthcare costs. However, it might temporarily limit access if few facilities initially qualify.
- On International Relations: No direct impacts, as the bill focuses on domestic Medicare policy.
Main Stakeholders Affected
- Medicare Beneficiaries: Patients receiving electrodiagnostic tests, who gain protections against substandard care.
- Healthcare Providers: Physicians, physical therapists (especially those certified in electrophysiology), and technicians performing these services; they must meet new training and facility standards or risk losing Medicare reimbursement.
- Facilities and Labs: Diagnostic centers and hospitals providing these tests, which must seek accreditation to continue billing Medicare.
- Accrediting Organizations: Groups that evaluate healthcare facilities, gaining opportunities to expand services but facing strict federal criteria.
- HHS and CMS: Responsible for implementation, regulation, and oversight.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens Medicare's fraud prevention under existing anti-abuse authorities (e.g., False Claims Act), potentially leading to more enforcement actions against non-compliant providers. The bill's delayed implementation (3–4 years) allows time for compliance, reducing legal challenges from abrupt changes.
- Constitutional: No apparent issues; it regulates federal spending (Medicare) without infringing on free speech, due process, or state powers, as healthcare accreditation often involves federal-state partnerships.
- Political: Could appeal to efforts to control healthcare costs and protect vulnerable populations, but may face pushback from providers concerned about added bureaucracy or barriers to care in underserved areas. The bipartisan sponsorship (introduced by Reps. Sessions, Weber, and Smucker) suggests broad support for quality improvements in Medicare.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Rep. Weber, Randy K. Sr. [R-TX-14], Rep. Smucker, Lloyd [R-PA-11]
Recent Actions
- 2025-04-30: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-04-30: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-04-30: Introduced in House
- 2025-04-30: Introduced in House
Bill Versions
- Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2025 — issued 2025-04-30 — PDF (8 pages)